The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
05
07
2018
accepted:
08
10
2018
revised:
29
08
2018
pubmed:
18
12
2018
medline:
21
5
2019
entrez:
18
12
2018
Statut:
ppublish
Résumé
B cell receptor (BCR) signaling is a central pathway promoting the survival and proliferation of normal and malignant B cells. Chronic lymphocytic leukemia (CLL) arises from mature B cells, expressing functional BCRs, mainly of immunoglobulin M (IgM) and IgD isotypes. Importantly, 30% of CLL patients express quasi-identical BCRs, the so-called "stereotyped" receptors, indicating the existence of common antigenic determinants, which may drive disease initiation and favor its progression. Although the antigenic specificity of IgM and IgD receptors is identical, there are distinct isotype-specific responses after IgM and IgD triggering. Here, we discuss the most important steps of normal B cell development, and highlight the importance of BCR signaling for CLL pathogenesis, with a focus on differences between IgM and IgD isotype signaling. We also highlight the main characteristics of CLL patient subsets, based on BCR stereotypy, and describe subset-specific BCR function and antigen-binding characteristics. Finally, we outline the key biologic and clinical responses to kinase inhibitor therapy, targeting the BCR-associated Bruton's tyrosine kinase, phosphoinositide-3-kinase, and spleen tyrosine kinase in patients with CLL.
Identifiants
pubmed: 30555163
doi: 10.1038/s41375-018-0303-x
pii: 10.1038/s41375-018-0303-x
pmc: PMC7182338
mid: NIHMS1575737
doi:
Substances chimiques
Immunoglobulin Isotypes
0
Receptors, Antigen, B-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-298Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : 9965
Pays : International
Organisme : UT | University of Texas MD Anderson Cancer Center (MD Anderson)
ID : CA016672
Pays : International
Références
Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18:148–67.
pubmed: 29348577
doi: 10.1038/nrc.2017.121
Xu Z, Zan H, Pone EJ, Mai T, Casali P. Immunoglobulin class-switch DNA recombination: induction, targeting and beyond. Nat Rev Immunol. 2012;12:517–31.
pubmed: 22728528
pmcid: 3545482
doi: 10.1038/nri3216
Mattila PK, Feest C, Depoil D, Treanor B, Montaner B, Otipoby KL, et al. The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling. Immunity. 2013;38:461–74.
pubmed: 23499492
doi: 10.1016/j.immuni.2012.11.019
Lutz C, Ledermann B, Kosco-Vilbois MH, Ochsenbein AF, Zinkernagel RM, Kohler G, et al. IgD can largely substitute for loss of IgM function in B cells. Nature. 1998;393:797–801.
pubmed: 9655395
doi: 10.1038/31716
Roes J, Rajewsky K. Immunoglobulin D (IgD)-deficient mice reveal an auxiliary receptor function for IgD in antigen-mediated recruitment of B cells. J Exp Med. 1993;177:45–55.
pubmed: 8418208
doi: 10.1084/jem.177.1.45
Ubelhart R, Hug E, Bach MP, Wossning T, Duhren-von MindenM, Horn AH, et al. Responsiveness of B cells is regulated by the hinge region of IgD. Nat Immunol. 2015;16:534–43.
pubmed: 25848865
doi: 10.1038/ni.3141
Kim KM, Reth M. The B cell antigen receptor of class IgD induces a stronger and more prolonged protein tyrosine phosphorylation than that of class IgM. J Exp Med. 1995;181:1005–14.
pubmed: 7869025
doi: 10.1084/jem.181.3.1005
Klasener K, Maity PC, Hobeika E, Yang J, Reth M. B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk. eLife. 2014;3:e02069.
pubmed: 24963139
pmcid: 4067077
doi: 10.7554/eLife.02069
Becker M, Hobeika E, Jumaa H, Reth M, Maity PC. CXCR4 signaling and function require the expression of the IgD-class B-cell antigen receptor. Proc Natl Acad Sci USA. 2017;114:5231–6.
pubmed: 28461496
doi: 10.1073/pnas.1621512114
pmcid: 5441763
Treanor B, Depoil D, Bruckbauer A, Batista FD. Dynamic cortical actin remodeling by ERM proteins controls BCR microcluster organization and integrity. J Exp Med. 2011;208:1055–68.
pubmed: 21482698
pmcid: 3092358
doi: 10.1084/jem.20101125
Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988;334:676–82.
pubmed: 3261841
doi: 10.1038/334676a0
Sabouri Z, Perotti S, Spierings E, Humburg P, Yabas M, Bergmann H, et al. IgD attenuates the IgM-induced anergy response in transitional and mature B cells. Nat Commun. 2016;7:13381.
pubmed: 27830696
pmcid: 5109548
doi: 10.1038/ncomms13381
Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thomas ML, Crabtree GR, et al. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity. 1997;6:419–28.
pubmed: 9133421
doi: 10.1016/S1074-7613(00)80285-X
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–54.
pubmed: 10477713
doi: 10.1182/blood.V94.6.1848
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–7.
pubmed: 10477712
doi: 10.1182/blood.V94.6.1840
D’Avola A, Drennan S, Tracy I, Henderson I, Chiecchio L, Larrayoz M, et al. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood. 2016;128:816–26.
doi: 10.1182/blood-2016-03-707786
pubmed: 27301861
Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood. 2012;119:4467–75.
pubmed: 22415752
pmcid: 3392073
doi: 10.1182/blood-2011-11-393694
Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109:259–70.
pubmed: 16985177
doi: 10.1182/blood-2006-03-012948
Baliakas P, Hadzidimitriou A, Sutton LA, Minga E, Agathangelidis A, Nichelatti M, et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematol. 2014;1:e74–e84.
pubmed: 27030157
doi: 10.1016/S2352-3026(14)00005-2
Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–74.
pubmed: 20940416
pmcid: 3031480
doi: 10.1182/blood-2010-05-284984
Palacios F, Moreno P, Morande P, Abreu C, Correa A, Porro V, et al. High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. Blood. 2010;115:4488–96.
pubmed: 20233972
doi: 10.1182/blood-2009-12-257758
Gounari M, Ntoufa S, Apollonio B, Papakonstantinou N, Ponzoni M, Chu CC, et al. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. Blood. 2015;125:3580–7.
pubmed: 25900981
pmcid: 4458798
doi: 10.1182/blood-2014-09-603217
Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012;209:2183–98.
pubmed: 23091163
pmcid: 3501361
doi: 10.1084/jem.20120833
Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, Boussiotis V, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112:188–95.
pubmed: 18292287
doi: 10.1182/blood-2007-09-111344
Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood. 2007;109:4424–31.
pubmed: 17255355
doi: 10.1182/blood-2006-11-056648
Apollonio B, Scielzo C, Bertilaccio MT, Ten Hacken E, Scarfo L, Ranghetti P, et al. Targeting B-cell anergy in chronic lymphocytic leukemia. Blood. 2013;121:3879–88. S3871-3878
pubmed: 23460614
doi: 10.1182/blood-2012-12-474718
Chen L, Widhopf G, Huynh L, Rassenti L, Rai KR, Weiss A, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609–14.
doi: 10.1182/blood-2002-06-1683
pubmed: 12393534
Vlad A, Deglesne PA, Letestu R, Saint-Georges S, Chevallier N, Baran-Marszak F, et al. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res. 2009;69:6387–95.
pubmed: 19654311
doi: 10.1158/0008-5472.CAN-08-4750
Chatzouli M, Ntoufa S, Papakonstantinou N, Chartomatsidou E, Anagnostopoulos A, Kollia P, et al. Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes. J Immunol. 2014;192:4518–24.
pubmed: 24719462
doi: 10.4049/jimmunol.1302102
Aguilar-Hernandez MM, Blunt MD, Dobson R, Yeomans A, Thirdborough S, Larrayoz M, et al. IL-4 enhances expression and function of surface IgM in CLL cells. Blood. 2016;127:3015–25.
pubmed: 27002119
doi: 10.1182/blood-2015-11-682906
Guo B, Zhang L, Chiorazzi N, Rothstein TL. IL-4 rescues surface IgM expression in chronic lymphocytic leukemia. Blood. 2016;128:553–62.
pubmed: 27226435
pmcid: 4965907
doi: 10.1182/blood-2015-11-682997
Ten Hacken E, Sivina M, Kim E, O’Brien S, Wierda WG, Ferrajoli A et al. Functional differences between IgM and IgD signaling in chronic lymphocytic leukemia. J Immunol. 2016;197:2522–31.
pubmed: 27534555
doi: 10.4049/jimmunol.1600915
Krysov S, Dias S, Paterson A, Mockridge CI, Potter KN, Smith KA, et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood. 2012;119:170–9.
pubmed: 22086413
doi: 10.1182/blood-2011-07-370403
Chu CC, Catera R, Zhang L, Didier S, Agagnina BM, Damle RN, et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood. 2010;115:3907–15.
pubmed: 20110421
pmcid: 2869555
doi: 10.1182/blood-2009-09-244251
Lanemo Myhrinder A, Hellqvist E, Sidorova E, Soderberg A, Baxendale H, Dahle C, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111:3838–48.
pubmed: 18223168
doi: 10.1182/blood-2007-11-125450
Jimenez de Oya N, De Giovanni M, Fioravanti J, Ubelhart R, Di Lucia P, Fiocchi A, et al. Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens. EMBO Mol Med. 2017;9:1482–90.
pubmed: 28899929
pmcid: 5666309
doi: 10.15252/emmm.201707732
Hoogeboom R, van Kessel KP, Hochstenbach F, Wormhoudt TA, Reinten RJ, Wagner K, et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med. 2013;210:59–70.
pubmed: 23296468
pmcid: 3549718
doi: 10.1084/jem.20121801
Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood. 2009;113:3050–8.
pubmed: 19074730
pmcid: 4916945
doi: 10.1182/blood-2008-07-170415
Duhren-von MindenM, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489:309–12.
doi: 10.1038/nature11309
Minici C, Gounari M, Ubelhart R, Scarfo L, Duhren-von MindenM, Schneider D, et al. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun. 2017;8:15746.
pubmed: 28598442
pmcid: 5472768
doi: 10.1038/ncomms15746
Iacovelli S, Hug E, Bennardo S, Duehren-von MindenM, Gobessi S, Rinaldi A, et al. Two types of BCR interactions are positively selected during leukemia development in the Emu-TCL1 transgenic mouse model of CLL. Blood. 2015;125:1578–88.
pubmed: 25564405
pmcid: 4351506
doi: 10.1182/blood-2014-07-587790
Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200:519–25.
pubmed: 15314077
pmcid: 2211936
doi: 10.1084/jem.20040544
Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111:1524–33.
pubmed: 17959859
doi: 10.1182/blood-2007-07-099564
Agathangelidis A, Hadzidimitriou A, Minga E, Sutton L, Polychronidou E, Shanafelt T, et al. Reappraising immunoglobulin repertoire restrictions in chronic lymphocytic leukemia: focus on major stereotyped subsets and closely related satellites. Blood. 2016;128:4376.
doi: 10.1182/blood.V128.22.4376.4376
Ntoufa S, Vardi A, Papakonstantinou N, Anagnostopoulos A, Aleporou-Marinou V, Belessi C, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med. 2012;18:1281–91.
pubmed: 22437326
pmcid: 3521790
doi: 10.2119/molmed.2011.00480
Ntoufa S, Papakonstantinou N, Apollonio B, Gounari M, Galigalidou C, Fonte E, et al. B cell anergy modulated by TLR1/2 and the miR-17 approximately 92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4. J Immunol. 2016;196:4410–7.
pubmed: 27059597
doi: 10.4049/jimmunol.1502297
Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, et al. Not all IGHV3–21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015;125:856–9.
pubmed: 25634617
pmcid: 4311230
doi: 10.1182/blood-2014-09-600874
Del Giudice I, Chiaretti S, Santangelo S, Tavolaro S, Peragine N, Marinelli M, et al. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients’ prognosis. Am J Hematol. 2014;89:74–82.
pubmed: 24030933
doi: 10.1002/ajh.23591
Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016;101:959–67.
pubmed: 27198719
pmcid: 4967575
doi: 10.3324/haematol.2016.141812
Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013;121:4902–5.
pubmed: 23637131
doi: 10.1182/blood-2013-02-486209
Mansouri L, Sutton LA, Ljungstrom V, Bondza S, Arngarden L, Bhoi S, et al. Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015;212:833–43.
pubmed: 25987724
pmcid: 4451125
doi: 10.1084/jem.20142009
Bergh AC, Evaldsson C, Pedersen LB, Geisler C, Stamatopoulos K, Rosenquist R, et al. Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia. Haematologica. 2014;99:1722–30.
pubmed: 25085355
pmcid: 4222481
doi: 10.3324/haematol.2014.106054
Stamatopoulos B, Smith T, Crompot E, Pieters K, Clifford R, Mraz M, et al. The light chain IgLV3–21 defines a new poor prognostic subgroup in chronic lymphocytic leukemia: results of a multicenter study. Clin Cancer Res. 2018;24:5048–57.
Jang YJ, Stollar BD. Anti-DNA antibodies: aspects of structure and pathogenicity. Cell Mol Life Sci. 2003;60:309–20.
pubmed: 12678496
doi: 10.1007/s000180300026
Kostareli E, Sutton LA, Hadzidimitriou A, Darzentas N, Kouvatsi A, Tsaftaris A, et al. Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution. Leukemia. 2010;24:1317–24.
pubmed: 20463750
doi: 10.1038/leu.2010.90
Sutton LA, Kostareli E, Hadzidimitriou A, Darzentas N, Tsaftaris A, Anagnostopoulos A, et al. Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen. Blood. 2009;114:4460–8.
pubmed: 19713457
doi: 10.1182/blood-2009-05-221309
Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009;15:4415–22.
pubmed: 19509140
doi: 10.1158/1078-0432.CCR-08-3266
Forconi F, Potter KN, Wheatley I, Darzentas N, Sozzi E, Stamatopoulos K, et al. The normal IGHV1–69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood. 2010;115:71–77.
pubmed: 19887677
doi: 10.1182/blood-2009-06-225813
Vergani S, Bagnara D, Mazzarello AN, Ferrer G, Yancopoulos S, Stamatopoulos K, et al. CLL atereotyped IGHV-D–J rearrangements can be detected throughout normal B-cell developmental stages in aged people when using ultra-deep, next generation sequencing techniques. Blood. 2016;128:2028.
doi: 10.1182/blood.V128.22.2028.2028
Catera R, Silverman GJ, Hatzi K, Seiler T, Didier S, Zhang L, et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med. 2008;14:665–74.
pubmed: 19009014
pmcid: 2582860
doi: 10.2119/2008-00102.Catera
Binder M, Lechenne B, Ummanni R, Scharf C, Balabanov S, Trusch M, et al. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS ONE. 2010;5:e15992.
pubmed: 21209908
pmcid: 3012720
doi: 10.1371/journal.pone.0015992
Ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfo L, Kim E, et al. Calreticulin as a novel B cell receptor antigen in chronic lymphocytic leukemia. Haematologica. 2017;102(10):e394–6.
pubmed: 28751563
pmcid: 5622869
doi: 10.3324/haematol.2017.169102
Mimmi S, Vecchio E, Iaccino E, Rossi M, Lupia A, Albano F, et al. Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. Leukemia. 2016;30:2419–22.
pubmed: 27568521
pmcid: 5155031
doi: 10.1038/leu.2016.245
Ghia EM, Widhopf GF 2nd, Rassenti LZ, Kipps TJ. Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia. J Immunol. 2011;186:6338–44.
pubmed: 21525382
doi: 10.4049/jimmunol.0902875
Liu Y, Catera R, Gao C, Yan XJ, Allen SL, Kolitz JE, et al. CLL stereotyped subset #4 Igs acquire binding to viable B Lymphocyte surfaces by somatic mutations, isotype class swtiching, and with the prerequisite of Ig self-association. Blood. 2017;130:58.
Catera R, Liu Y, Gao C, Yan XJ, Magli A, Allen SL, et al. Binding of CLL subset 4 B-cell receptor immunoglobulins to viable human memory B lymphocytes requires a distinctive IGKV somatic mutation. Mol Med. 2017;23:1–12.
pubmed: 28097289
pmcid: 5364113
doi: 10.2119/molmed.2017.00003
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578–85.
pubmed: 19965662
pmcid: 2852362
doi: 10.1182/blood-2009-08-236471
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Eng J Med. 2013;369:32–42.
doi: 10.1056/NEJMoa1215637
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Eng J Med. 2014;370:997–1007.
doi: 10.1056/NEJMoa1315226
Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Eng J Med. 2015;373:2425–37.
doi: 10.1056/NEJMoa1509388
Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, et al. CAL-101, ap110{delta} selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–4.
pubmed: 20959606
pmcid: 3694505
doi: 10.1182/blood-2010-03-275305
Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, et al. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014;123:4132–5.
pubmed: 24829205
pmcid: 4123432
doi: 10.1182/blood-2014-02-554220
Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight. 2017;2:e89904.
pubmed: 28138560
pmcid: 5256142
doi: 10.1172/jci.insight.89904
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–9.
pubmed: 22180443
pmcid: 4916557
doi: 10.1182/blood-2011-10-386417
de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590–4.
pubmed: 22279054
doi: 10.1182/blood-2011-11-390989
Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118:3603–12.
pubmed: 21803855
pmcid: 4916562
doi: 10.1182/blood-2011-05-352492
Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton’s tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–96.
pubmed: 21422473
pmcid: 3122947
doi: 10.1182/blood-2011-01-328484
Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O’Brien S, et al. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS ONE. 2013;8:e83830.
pubmed: 24376763
pmcid: 3871531
doi: 10.1371/journal.pone.0083830
Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget. 2016;7:4598–610.
pubmed: 26717038
doi: 10.18632/oncotarget.6727
Ahn IE, Farooqui MZH, Tian X, Valdez J, Sun C, Soto S, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131:2357–66.
pubmed: 29483101
pmcid: 5969380
doi: 10.1182/blood-2017-12-820910
Burger JA, O’Brien S. Evolution of CLL treatment—from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15:510–27.
pubmed: 29777163
doi: 10.1038/s41571-018-0037-8
Ryan CE, Sahaf B, Logan AC, O’Brien S, Byrd JC, Hillmen P, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128:2899–908.
pubmed: 27802969
pmcid: 5179333
doi: 10.1182/blood-2016-06-715284
Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117–27.
pubmed: 26813675
pmcid: 4778162
doi: 10.1182/blood-2015-11-679134
Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O’Brien S, et al. Ibrutinib therapy increases T cell repertoire diversity in patients with chronic lymphocytic leukemia. J Immunol. 2017;198:1740–7.
Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–49.
pubmed: 23886836
pmcid: 3795457
doi: 10.1182/blood-2013-06-507947
Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127:3052–64.
pubmed: 28714866
pmcid: 5531425
doi: 10.1172/JCI89756
O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018;131:1910–9.
pubmed: 29437592
pmcid: 5921964
doi: 10.1182/blood-2017-10-810044
Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Eng J Med. 2014;370:2286–94.
doi: 10.1056/NEJMoa1400029
Ahn IE, Underbayev C, Albitar A, Herman SE, Tian X, Maric I, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129:1469–79.
pubmed: 28049639
pmcid: 5356450
doi: 10.1182/blood-2016-06-719294
Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589.
pubmed: 27199251
pmcid: 4876453
doi: 10.1038/ncomms11589
Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8:2185.
pubmed: 29259203
pmcid: 5736707
doi: 10.1038/s41467-017-02329-y
Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, et al. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood. 2016;128:3101–12.
Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 2015;125:3128–32.
pubmed: 25838351
pmcid: 4432007
doi: 10.1182/blood-2015-01-621391
Saba NS, Wong DH, Tanios G, Iyer JR, Lobelle-Rich P, Dadashian EL, et al. MALT1 inhibition is efficacious in both naive and ibrutinib-resistant chronic lymphocytic leukemia. Cancer Res. 2017;77:7038–48.
pubmed: 28993409
pmcid: 5732856
doi: 10.1158/0008-5472.CAN-17-2485
Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, et al. The BTK inhibitor ARQ 531 targets ibrutinib resistant CLL and Richter’s transformation. Cancer Discov. 2018;8:1300–15.
pubmed: 30093506
doi: 10.1158/2159-8290.CD-17-1409
pmcid: 6261467
Guisot NES, Best SA, Wright V, Thomason A, Woyach JA, Mantel R, et al. REDX08608, a novel, potent and selective, reversible BTK inhibitor with efficacy and equivalent potency against wild-type and mutant C481S BTK. Blood. 2016;128:4399.
doi: 10.1182/blood.V128.22.4399.4399
Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.
pubmed: 26641137
doi: 10.1056/NEJMoa1509981
Awan FT, Schuh A, Brown JR, Furman R, Pagel JM, Hillmen P, et al. Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1/2 ACE-CL-001 clinical study. Blood. 2016; 638. ASH annual meeting abstract.
Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127:411–9.
pubmed: 26542378
pmcid: 4731845
doi: 10.1182/blood-2015-08-664086
Tam CS, Opat S, Cull G, Trotman J, Gottlieb D, Simpson D, et al. Twice daily dosing with the highly specific BTK inhibitor, Bgb-3111, achieves complete and continuous BTK occupancy in lymph nodes, and is associated with durable responses in patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Blood. 2016: 642. ASH annual meeting abstract.
Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014;124:3583–6.
pubmed: 25258342
pmcid: 4256910
doi: 10.1182/blood-2014-07-587279
Brown JR, Davids MS, Rodon J, Abrisqueta P, Kasar SN, Lager J, et al. Phase I trial of the pan-PI3K inhibitor pilaralisib (SAR245408/XL147) in patients with chronic lymphocytic leukemia (CLL) or relapsed/refractory lymphoma. Clin Cancer Res. 2015;21:3160–9.
pubmed: 25840972
doi: 10.1158/1078-0432.CCR-14-3262
Kater AP, Tonino SH, Spiering M, Chamuleau MED, Liu R, Adewoye AH, et al. Final results of a phase 1b study of the safety and efficacy of the PI3Kdelta inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood Cancer J. 2018;8:16.
pubmed: 29434192
pmcid: 5809482
doi: 10.1038/s41408-018-0055-x
Niemann CU, Mora-Jensen HI, Dadashian EL, Krantz F, Covey T, Chen SS, et al. Combined BTK and PI3Kdelta inhibition with acalabrutinib and ACP-319 improves survival and tumor control in CLL mouse model. Clin Cancer Res. 2017;23:5814–23.
pubmed: 28645939
pmcid: 5626587
doi: 10.1158/1078-0432.CCR-17-0650
Maharaj KK, Powers JJ, Pabon-Saldana M, Fonseca R, Achille A, Deng S, et al. Modulation of T cell compartment in a preclinical CLL murine model by a selective PI3K delta inhibitor, TGR-1202. Blood. 2016;128:3236.
doi: 10.1182/blood.V128.22.3236.3236
Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, et al. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406. Blood. 2009;114:1029–37.
pubmed: 19491390
pmcid: 4916941
doi: 10.1182/blood-2009-03-212837
Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;125:2336–43.
pubmed: 25696919
pmcid: 4401348
doi: 10.1182/blood-2014-08-595934